Total Payments
$33,487
2024 Payments
$750.00
Companies
5
Transactions
43
Medicare Patients
566
Medicare Billing
$51,596
Payment Breakdown by Category
Consulting$23,988 (71.6%)
Other$6,453 (19.3%)
Travel$2,290 (6.8%)
Food & Beverage$757.31 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $23,988 | 14 | 71.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,453 | 1 | 19.3% |
| Travel and Lodging | $2,290 | 14 | 6.8% |
| Food and Beverage | $757.31 | 14 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | $10,771 | 7 | $0 (2021) |
| Kyowa Kirin, Inc. | $7,931 | 15 | $0 (2023) |
| AbbVie Inc. | $6,196 | 10 | $0 (2023) |
| Alexion Pharmaceuticals, Inc. | $4,614 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $3,975 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $750.00 | 1 | Merck Sharp & Dohme LLC ($750.00) |
| 2023 | $19,491 | 29 | Kyowa Kirin, Inc. ($7,931) |
| 2022 | $450.00 | 1 | Merck Sharp & Dohme LLC ($450.00) |
| 2021 | $7,650 | 3 | Ultragenyx Pharmaceutical Inc. ($7,200) |
| 2020 | $4,396 | 7 | Ultragenyx Pharmaceutical Inc. ($3,571) |
| 2019 | $375.00 | 1 | Merck Sharp & Dohme Corporation ($375.00) |
| 2018 | $375.00 | 1 | Merck Sharp & Dohme Corporation ($375.00) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,452.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $51.70 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 12/19/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $40.93 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/08/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: Rare Disease | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $98.23 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $44.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $44.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/28/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $403.80 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $323.50 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $171.20 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $119.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $111.63 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/27/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $23.54 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/12/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $113.69 | General |
| Category: Rare Disease | ||||||
| 09/15/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $26.46 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 07/17/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 06/14/2023 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Rare Disease | ||||||
| 04/14/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $5,062.50 | General |
| 04/14/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $65.48 | General |
| 03/11/2023 | AbbVie Inc. | — | Travel and Lodging | In-kind items and services | $696.41 | General |
| 03/11/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 03/11/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $49.97 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 169 | 181 | $78,809 | $14,416 |
| 2022 | 4 | 183 | 203 | $91,046 | $17,602 |
| 2021 | 4 | 124 | 145 | $51,905 | $11,681 |
| 2020 | 4 | 90 | 120 | $37,280 | $7,897 |
Total Patients
566
Total Services
649
Medicare Billing
$51,596
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 37 | 43 | $17,394 | $3,389 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 29 | $15,763 | $3,239 | 20.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 41 | 43 | $16,615 | $2,787 | 16.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 38 | 40 | $10,980 | $2,029 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $10,088 | $1,737 | 17.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $7,969 | $1,235 | 15.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 59 | $23,511 | $4,856 | 20.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 44 | 46 | $24,476 | $4,469 | 18.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 35 | $13,205 | $2,475 | 18.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $9,450 | $1,811 | 19.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 14 | 14 | $7,790 | $1,510 | 19.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 21 | 25 | $6,742 | $1,297 | 19.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 11 | 11 | $5,872 | $1,183 | 20.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 48 | 57 | $18,675 | $4,085 | 21.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 25 | 26 | $11,984 | $2,844 | 23.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 23 | 23 | $10,436 | $2,123 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 11 | 20 | $6,662 | $1,654 | 24.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 19 | $4,148 | $975.11 | 23.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 36 | 42 | $12,890 | $2,769 | 21.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 30 | $8,730 | $1,901 | 21.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 20 | 21 | $6,485 | $1,368 | 21.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 15 | $6,717 | $1,366 | 20.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 11 | 12 | $2,458 | $493.40 | 20.1% |
About Julia Charles, M.D., PH.D
Julia Charles, M.D., PH.D is a Emergency Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164543252.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Julia Charles, M.D., PH.D has received a total of $33,487 in payments from pharmaceutical and medical device companies, with $750.00 received in 2024. These payments were reported across 43 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($23,988).
As a Medicare-enrolled provider, Charles has provided services to 566 Medicare beneficiaries, totaling 649 services with total Medicare billing of $51,596. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Other Specialties Rheumatology, Rheumatology
- Location Boston, MA
- Active Since 04/03/2007
- Last Updated 07/27/2020
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1164543252
Products in Payments
- Crysvita (Drug) $7,931
- STRENSIQ (Biological) $4,614
- Cryvista (Drug) $3,571
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Boston
Sunil Kapur, Md, MD
Emergency Medicine — Payments: $542,263
Emergency Medicine $542,263
Joshua Goldstein, Md, Phd, MD, PHD
Emergency Medicine — Payments: $340,169
Emergency Medicine $340,169
Elissa Perkins, Md, MD
Emergency Medicine — Payments: $250,334
Emergency Medicine $250,334
Adaira Landry, M.d, M.D
Emergency Medicine — Payments: $211,020
Emergency Medicine $211,020
Dr. Christopher Baugh, M.d., Mba, M.D., MBA
Emergency Medicine — Payments: $172,710
Emergency Medicine $172,710
Dr. John Nagurney, Md, MD
Emergency Medicine — Payments: $137,834
Emergency Medicine $137,834